Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LS-Q2
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences Peking Union Medical College
01
Overview
LS-Q2: sourced facts only. name: "Further biological and in vivo pharmacokinetic evaluation confirmed that derivative 6m (LS-Q2) is a novel, orally bioavailable, and highly selective CDK4/9 inhibitor with potent antiproliferative activity against various tumor cells." [PMID:41982721]; target: "Further biological and in vivo pharmacokinetic evaluation confirmed that derivative 6m (LS-Q2) is a novel, orally bioavailable, and highly selective CDK4/9 inhibitor with potent antiproliferative activity against various tumor cells." [PMID:41982721]; developer: "Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China." [PMID:41982721]
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on LS-Q2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LS-Q2.